• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20010 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Austrian Institute for Health Technology Assessment (AIHTA) National strategies and programmes for preventing and managing non-communicable diseases in selected countries
2021     Malaysian Health Technology Assessment (MaHTAS) Targeted therapies in combination with neoadjuvant chemotherapy for HER2-positive breast cancer and economic evaluation
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme A tailored, psychological intervention for mild to moderate anxiety or depression in people with chronic obstructive pulmonary disease(COPD) (TANDEM Tailored intervention for ANxiety and DEpression Management in COPD)
2021     Norwegian Institute of Public Health (NIPH) [Ofatumumab for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment – health economic evaluation]
2021     Center for Evidence-based Practice (CEP) Tracheostomy or endotracheal tubes and subglottic suctioning
2021     Malaysian Health Technology Assessment (MaHTAS) Therapeutic drug monitoring (TDM) for anti-tuberculosis
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme High Or Low Dose Syntocinon for delay in labour (HOLDS)
2021     NIHR Health Technology Assessment programme Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users
2021     Health Information and Quality Authority (HIQA) Review of international ethics frameworks used in policy-making in the context of screening
2021     Malaysian Health Technology Assessment (MaHTAS) Custodiol HTK as a replacement of blood cardioplegia in cardiac surgery
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risdiplam (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Specific rehabilitation interventions for physical impairment to avoid chronification of non-specific back pain in adults]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy and safety of onasemnogene abeparvovec, nusinersen and risdiplam for the treatment of spinal muscular atrophy]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Prevention of tuberculosis reactivation
2021     Malaysian Health Technology Assessment (MaHTAS) Mobile C-arm fluoroscopy for cardiothoracic surgery
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     NIHR Health Technology Assessment programme Specific versus generic psychological therapy for adolescents with social anxiety disorder: a comparison of Clark & Wells condition-specific cognitive therapy adapted for adolescents, with the generic cognitive behaviour therapy that is currently used in adolescent services
2021     Center for Evidence-based Practice (CEP) Opioids for vaso-occlusive crisis in pregnant patients
2021     NIHR Health Technology Assessment programme Improving continence in children and young people with neurodisability: a systematic review and survey
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression, acute treatment) - Addendum to Commission A21-25]
2021     Haute Autorite de sante (HAS) [Remote monitoring of patients with an implantable loop recorder]
2021     Center for Evidence-based Practice (CEP) COVID-19: vaccination for women who are pregnant or lactating
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of newborn screening for spinal muscular atrophy]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (urothelial carcinoma) - Addendum to Commission A21-23]
2021     Center for Evidence-based Practice (CEP) COVID-19: management of vaccine-associated thrombotic syndromes
2021     Swiss Federal Office of Public Health (FOPH) Effectiveness and safety of vitamin B12 tests
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Yttrium-90 microspheres for intermediate- or advanced-stage hepatocellular carcinoma
2021     Malaysian Health Technology Assessment (MaHTAS) Viscoelastic haemostatic assay for non-cardiac surgery
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for stem cell transplantation - Update of commission V18-02]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Gender-specific differences in drug effects. Exemplary analysis based on beta-adrenoceptor antagonists as cardiac therapy and antidepressants as psychotropic drugs]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: advisability of using molecular tests to clarify the diagnosis of thyroid nodules with indeterminate cytology]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy and safety of buprenorphine and methadone for the treatment of opioid use disorder]
2021     Andalusian Health Technology Assessment Area (AETSA) [Laser interstitial thermal therapy for patients with refractory epilepsy: safety and effectiveness. A systematic review]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: timing of nutrition in acute pancreatitis]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Smoking bans in public places]
2021     NIHR Health Technology Assessment programme CONservative TReatment of Appendicitis in Children a randomised controlled Trial CONTRACT (Feasibility study)
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: challenging behaviours - best practices in prevention, assessment and Intervention for people with an intellectual disability, physical disability or autism spectrum disorder]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: care pathways leading to the diagnostic assessment of neurodevelopmental disorders in children 0-7 years old]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional interventions in chronic pancreatitis]
2021     NIHR Health Services and Delivery Research programme Acute Day Units as Crisis Alternatives to Residential Care AD-CARE
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: oral opioid agonists for the treatment of opioid use disorder]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of and indications for submitting surgical specimens to the anatomic pathology laboratory: obstetrics/gynecology and urology]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Abiraterone acetate for metastatic castration-sensitive prostate cancer
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Remote monitoring programs for cardiac conditions
2021     Center for Evidence-based Practice (CEP) COVID-19: effects of vaccines on fertility and pregnancy outcomes
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of and indications for submitting surgical specimens to the anatomic pathology laboratory: general surgery, plastic surgery and dermatology]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Bisphosphonate drugs for the treatment of osteoporosis in post-menopausal women
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (follicular lymphoma, after rituximab) - Benefit assessment according to §35a Social Code Book V]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Radiation exposure by medical X-ray applications]
2021     NIHR Health Technology Assessment programme Minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy for mitral valve repair: a multicentre randomised controlled trial (UK Mini Mitral)
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organization of care and services related to alternate levels of care (ALC)]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: optimal use of immunoglobulins in infectious diseases]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Direct oral anticoagulants for atrial fibrillation [evidence update]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Music therapy for adolescents with mental and behavioural disorders]
2021     NIHR Health Technology Assessment programme Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM) trial
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: portrait of the use of home care and support services by people at the end-stages of life in Québec, 2013-2018]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Interventions to address and prevent violence toward health care workers in the emergency department
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide and dexamethasone) - Benefit assessment according to §35a Social Code Book V]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Effects of life style changes in persons with prediabetes]
2021     NIHR Health Technology Assessment programme Understanding health-care outcomes of older people with cognitive impairment and/or dementia admitted to hospital: a mixed-methods study
2021     NIHR Health Technology Assessment programme Antidepressants to prevent relapse in depression
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Amikacin (Mycobacterium avium complex pulmonary infections)]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Hybrid closed-loop insulin delivery systems for people with Type 1 diabetes
2021     Health Technology Wales (HTW) Transcranial magnetic stimulation for the treatment of depression
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Onasemnogene abeparvovec (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Mistletoe therapy with breast cancer]
2021     NIHR Health Technology Assessment programme BioImpedance Spectroscopy To maintain Renal Output: the BISTRO trial
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Atidarsagen autotemcel (metachromatic leukodystrophy with biallelic mutation in the ARSA gene)]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cannabidiol (seizures in tuberous sclerosis complex) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Coping strategies in complex medical situations - the example of coronary heart disease]
2021     NIHR Health Services and Delivery Research programme Models of generalist and specialist care in smaller acute hospitals: an exploratory study
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: noninvasive fetal RhD genotyping using maternal plasma]
2021     Scottish Health Technologies Group (SHTG) Detection of paroxysmal atrial fibrillation in patients with newly diagnosed ischaemic stroke
2021     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Autologous anti-CD19-transduced CD3+ cells (mantle cell lymphoma, pretreated patients)]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice ravulizumab (Ultomiris®) for the treatment of PNH and aHUS
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obinutuzumab (follicular lymphoma, first line) - Benefit assessment according to §35a Social Code Book V]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [The potential influence of socio-demographical factors on access to and results of rehabilitation]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS advice tirbanibulin (Klisyri®) for the treatment of adults with actinic keratosis
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tucatinib (breast cancer) - Addendum to Commission A21-26]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice venetoclax (Venclyxto®)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lanadelumab (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V]
2021     Canadian Agency for Drugs and Technologies in Health (CADTH) Stereotactic ablative radiotherapy for the treatment of oligometastatic cancer: a clinical review as part of a health technology assessment v1.0
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment ponesimod (Ponvory®) for the treatment of relapsing forms of multiple sclerosis (RMS)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on clinical nutrition in gastroenterology - Pancreas: nutritional supplementation in acute pancreatitis]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Speech therapy for aphasia]
2021     Swiss Federal Office of Public Health (FOPH) Statins in the primary prevention of cardiovascular events and mortality in Switzerland
2021     NIHR Health Technology Assessment programme Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: microbiological stool testing in adults and children with diarrhea: relevance and measures to promote judicious use]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice cemiplimab (Libtayo®) for the treatment of non-small cell lung carcinoma (NSCLC)
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (Hodgkin lymphoma) - Addendum to Commission A21-35]
2021     Swiss Federal Office of Public Health (FOPH) Vertebroplasty or kyphoplasty in painful osteoporotic vertebral compression fractures unresponsive to non-surgical treatment
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: pertussis - diagnostic modalities and trajectory]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment empagliflozin (Jardiance®) for the treatment of adults with chronic heart failure
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avatrombopag (thrombocytopenia) - Addendum to Commission A21-31]
2021     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS review levomepromazine (Nozinan®) for palliative sedation in a home situation
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (colorectal cancer) - Addendum to Commission A21-36]